JULIA FIORE: Open Payments
NPI 1215331384 · AGAWAM, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,711 in 182 payments from 22 companies in 2025. Trend: 2023 $2,295 · 2024 $4,476 · 2025 $3,711
Food & beverage: $3,532Education: $179
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 42 | $667 |
| UCB, Inc. | 26 | $443 |
| Novartis Pharmaceuticals Corporation | 16 | $347 |
| Janssen Biotech, Inc. | 11 | $283 |
| Regeneron Healthcare Solutions, Inc. | 4 | $260 |
| GENZYME CORPORATION | 7 | $259 |
| Arcutis Biotherapeutics, Inc. | 14 | $252 |
| Galderma Laboratories, L.P. | 14 | $224 |
| E.R. Squibb & Sons, L.L.C. | 12 | $214 |
| Lilly USA, LLC | 10 | $204 |
Products named: DUPIXENT, Bimzelx, SKYRIZI, TREMFYA, Zoryve, RINVOQ, COSENTYX, Sotyktu.
Industry payments across MA — which companies pay providers there.
